These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9922319)

  • 21. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
    Romero-Gómez M; Del Mar Viloria M; Andrade RJ; Salmerón J; Diago M; Fernández-Rodríguez CM; Corpas R; Cruz M; Grande L; Vázquez L; Muñoz-De-Rueda P; López-Serrano P; Gila A; Gutiérrez ML; Pérez C; Ruiz-Extremera A; Suárez E; Castillo J
    Gastroenterology; 2005 Mar; 128(3):636-41. PubMed ID: 15765399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response.
    Floreani A; Cazzagon N; Boemo DG; Baldovin T; Baldo V; Egoue J; Antoniazzi S; Minola E
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):997-1003. PubMed ID: 21915057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
    Cammà C; Di Bona D; Schepis F; Heathcote EJ; Zeuzem S; Pockros PJ; Marcellin P; Balart L; Alberti A; Craxì A
    Hepatology; 2004 Feb; 39(2):333-42. PubMed ID: 14767986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
    Carrión JA; Navasa M; García-Retortillo M; García-Pagan JC; Crespo G; Bruguera M; Bosch J; Forns X
    Gastroenterology; 2007 May; 132(5):1746-56. PubMed ID: 17484872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
    Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
    Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.
    Poynard T; McHutchison J; Manns M; Trepo C; Lindsay K; Goodman Z; Ling MH; Albrecht J
    Gastroenterology; 2002 May; 122(5):1303-13. PubMed ID: 11984517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
    Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
    J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Berg T; Neuhaus R; Neuhaus P
    Transplantation; 2007 Feb; 83(3):351-3. PubMed ID: 17297412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients.
    Abdel-Rahman M; Saad Y; El-Raziky M; Zayed N; El-Akel W; Said M; El-Beshlawy M; Esmat G
    Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):479-84. PubMed ID: 23540379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of a high-intensity interferon-alpha regimen for chronic hepatitis C virus genotype 1b infection.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Tanikawa M; Sone Y; Hisanaga Y; Hayashi K
    Hepatogastroenterology; 2002; 49(48):1619-24. PubMed ID: 12397749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
    Lamers MH; Broekman M; Drenth JP; Gluud C
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
    Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
    Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
    Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.